Akili Inc. (AKLI)
0.43
-0.00 (-0.46%)
At close: Jul 01, 2024, 8:00 PM
0.43
-0.25%
After-hours: Jul 01, 2024, 04:00 PM EDT
Company Description
Akili, Inc., a digital medicine company, develops digital therapeutics for cognitive impairments.
It provides EndeavorRx, a physician-prescribed video game-based treatment designed to directly target cognitive functioning.
The company is based in Boston, Massachusetts.
Akili Inc.
| Country | United States |
| IPO Date | Jun 30, 2021 |
| Industry | Medical - Healthcare Information Services |
| Sector | Healthcare |
| Employees | 68 |
| CEO | Matthew Franklin M.B.A. |
Contact Details
Address: 125 Broad Street Boston, Massachusetts United States | |
| Website | https://www.akiliinteractive.com |
Stock Details
| Ticker Symbol | AKLI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001850266 |
| CUSIP Number | 00974B107 |
| ISIN Number | US00974B1070 |
| Employer ID | 98-1586159 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Matthew Franklin M.B.A. | President, Chief Executive Officer & Director |
| Jacqueline L. Studer J.D. | Chief Legal Officer, General Counsel & Secretary |
| Dr. Adam Gazzaley M.D., Ph.D. | Co-Founder, Chief Science Advisor & Director |
| Dr. Walter Edward Martucci II, Ph.D. | Co-Founder & Chairman |
| Jonathan David | Chief Product Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 13, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 09, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 05, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 12, 2024 | 15-12G | Filing |
| Jul 09, 2024 | SC 13D/A | [Amend] Filing |
| Jul 08, 2024 | 4 | Filing |
| Jul 05, 2024 | 4 | Filing |
| Jul 05, 2024 | SC 13D/A | [Amend] Filing |
| Jul 05, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 05, 2024 | 4 | Filing |